We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of ProTectis on Infant Colic and Its Effect on Infant Crying Time and Maternal Mental Health (PRIC-SMM)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2014 by Dr. Parveen Akhtar, Ferozsons Laboratories Ltd..
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT02094092
First Posted: March 21, 2014
Last Update Posted: March 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. Parveen Akhtar, Ferozsons Laboratories Ltd.
  Purpose

This study will work on hypothetical assumption that compared to the arm supplemented with placebo (control) group; the L reuteri (intervention) group will lower daily crying/fussing time per 24 hours at one month post randomization. And that the L reuteri (intervention) group at 7, 14, 21, days and 1 week after the therapy cessation will have:

  • Lower crying/fussing time per 24 hours.
  • Relief from colic pain
  • Longer sleep duration,
  • Higher scores on a standardized measure of maternal mental health

Condition Intervention
Infantile Colic Infant Sleeping Habits Maternal Mental Health. Other: ProTectis drops (five drops per day) for 21 days Other: Placebo drops (five drops per day) for 21 days

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: L.Reuteri ProTectis DSM 17938 to Relieve Infant Colic and Its Effects on Infant Sleep Pattern & Maternal Mental Health. PRIC-SMM Trial

Resource links provided by NLM:


Further study details as provided by Dr. Parveen Akhtar, Ferozsons Laboratories Ltd.:

Primary Outcome Measures:
  • The treatment success (defined as the percentage of children achieving a reduction in the daily average crying time 50% during the study) [ Time Frame: Day 28 ]
  • Change in the duration of crying (minutes per day). [ Time Frame: Base line, day 7, day 14, day 21 & day 28 ]

Secondary Outcome Measures:
  • A reduction in the daily average crying time, to <3 h/d. [ Time Frame: Day 21 ]
  • Change in Infant sleep duration in (minutes/day) [ Time Frame: Baseline, day 7, day 14, day 21& day 28 ]
  • Change in Maternal mental health scores. [ Time Frame: Baseline, day 21 & day 28 ]

Other Outcome Measures:
  • Persistence of infantile colic after the intervention. [ Time Frame: Day 28 ]
  • Change in the Parental perceptions of colic severity [ Time Frame: Baseline, day 7, day 14, day 21 & day 28 ]
  • Change in the Parental/ family quality of life [ Time Frame: Baseline, day 21 & day 28 ]

Estimated Enrollment: 60
Study Start Date: May 2014
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: ProTectis drops
Arm A.
Other: ProTectis drops (five drops per day) for 21 days
Placebo Comparator: Placebo drops
Arm B
Other: Placebo drops (five drops per day) for 21 days

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 3 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All infants (Full term with gestational age > 37 weeks and < 41 weeks) aged <3 months with infantile colic (defined as crying episodes lasting 3 or more hours/day and occurring at least 3 days/week within 7 days prior to enrollment)
  • Infants who were exclusively or predominantly (>50%) breastfed/fed on Fresh Milk i.e.; cow milk/buffalo/tetra pack.

Exclusion Criteria:

  • Acute or chronic illness
  • Gastrointestinal disorders
  • Use of any antibiotics and/or probiotic pharmaceutical products within 7 days prior to the study.
  • Infants taking Probiotic containing infant formula milks.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02094092


Locations
Pakistan
Fauji Foundation Hospital Not yet recruiting
Rawalpindi, Punjab, Pakistan
Contact: Parveen Akhtar, Dr    +92-515788104    pervtariq@hotmail.com   
Principal Investigator: Perveen Akhtar, Dr.         
Sponsors and Collaborators
Ferozsons Laboratories Ltd.
Investigators
Principal Investigator: Parveen Akhter, Dr. Fauji Foundation Hospital, Rawalpindi
  More Information

Responsible Party: Dr. Parveen Akhtar, Head of Pediatric Department, Fauji Foundation Hospital, Ferozsons Laboratories Ltd.
ClinicalTrials.gov Identifier: NCT02094092     History of Changes
Other Study ID Numbers: FZSPBT001
First Submitted: March 13, 2014
First Posted: March 21, 2014
Last Update Posted: March 21, 2014
Last Verified: March 2014

Keywords provided by Dr. Parveen Akhtar, Ferozsons Laboratories Ltd.:
L.reuteri ProTectis DSM 17938
Infantile colic
Maternal mental health.
Infant crying/fussing
Edinburgh Postnatal Depression Scale (EPDS)

Additional relevant MeSH terms:
Colic
Infant, Newborn, Diseases